title: Does Therapeutic Drug Monitoring of Ribavirin in HCV Genotype 3 Treatment With Sofosbuvir and Ribavirin Still Have a Role?
authors.affiliation: *Department of Virology, Amiens University Medical Center †Virology Research Unit, EA 4294, Jules Verne University of Picardie ‡Department of Pharmacology, Amiens University Medical Center, Amiens, France.
authors.forename: Etienne
authors.initials: E
authors.lastname: Brochot
authors.forename: Sandra
authors.initials: S
authors.lastname: Bodeau
authors.forename: Gilles
authors.initials: G
authors.lastname: Duverlie
mesh_terms: D000998:Antiviral Agents / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D012254:Ribavirin / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use*; D000069474:Sofosbuvir / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D000069474:Sofosbuvir